Amyotrophic Lateral Sclerosis (ALS)

ALS TDI Posts Quarterly Research Update

The ALS Therapy Development Institute’s second-quarter Research Update discussed new thinking about how ALS develops and progresses, and described progress in testing nearly 30 compounds targeting various ALS-related pathways.

Study to Probe Oxidative Stress in People With ALS

More than 400 people who recently received an ALS diagnosis are being sought for a large study of a cell-damaging phenomenon called "oxidative stress," common in ALS and other degenerative diseases.

Oxidative stress is a type of damage that results from high levels of toxic byproducts of energy production inside cells. These toxic chemicals — known as free radicals — normally are present, but when they're produced in excess or when cells become unable to detoxify them, they become dangerous.

‘Power for the Journey’ Gives Back to ALS Community

When you’re hoping to earn $14, but wind up making $20 instead, that’s good reason to be happy.

Marlene Zaleski and four of her friends found themselves in just such a situation, except the $14 was $14,000, and the final tally from their ALS fundraising run/walk in Cookeville, Tenn., on April 24 was not $20 but $20,118. All proceeds from the event went to MDA’s Augie’s Quest ALS research effort.

Fitness Giant Bally Goes All Out for Augie’s Quest

For the third year in a row, Bally Total Fitness is pulling out all the stops to raise funds for MDA’s Augie’s Quest ALS research initiative.  

Of Mice and Men: ALS TDI Discusses ALS Research Animals

Sean Scott, the late president of the ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., used to compare ALS to a building fire in which firemen show up focused on one thing: putting out the fire as quickly as possible.

Scott believed that same sense of urgency and focus should be directed at stopping ALS, recalled ALS TDI Director of Communications Rob Goldstein during an hour-long public webinar on June 29.

Participants Sought for Three ALS Trials

Research scientists are seeking individuals interested in participating in any of the following three trials in ALS.

High-fat, high-calorie diets

Enrollment is open in an MDA-supported study comparing three tube-feeding formulas – one high in calories; one high in fat calories; and one standard formula – in people with ALS.

Augie's New Book Extols Giving

When MDA ALS Division Co-Chair Augie Nieto was a young businessman just starting out, he had an idea that laid the groundwork for his later, multimillion-dollar success in the fitness industry. Instead of selling his unwanted exercise bikes at a loss, he sent 50 of them as gifts to health club owners across the country. Soon, orders started pouring in.

The Flip of a Switch

Neuraltus Pharmaceuticals of Palo Alto, Calif., is developing a small molecule whose target is regulation of immune system cells believed to contribute to neuroinflammation and disease progression in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

About ALS mechanisms  

ALS TDI: Changes in the Works

In its quarterly Research Update Webcast on May 18, 2010, the ALS Therapy Development Institute (ALS TDI) informed viewers of a "paradigm shift" in TDI research. The changes include the addition of a new mouse model to the Institute's preclinical drug development program and an increased emphasis on the importance of biological indicators called "biomarkers."

 The webinar also addressed the current state of drug development in ALS, and the ways in which ALS TDI hopes to hasten the process.

SOD1 Versus Other ALS: Apples and Oranges?

Scientists at Northwestern University Feinberg School of Medicine in Chicago have announced new findings showing some forms of familial and nonfamilial ("sporadic") amyotrophic lateral sclerosis (ALS) have commonalities at the molecular level — but that one form of familial ALS may be different.

Pages